CA2875205C - Therapeutic agent or prophylactic agent for dementia - Google Patents

Therapeutic agent or prophylactic agent for dementia Download PDF

Info

Publication number: CA2875205C
Authority: CA; Canada
Prior art keywords: seq; antibody; tau protein; tau; phosphorylated
Prior art date: 2012-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CA2875205A

Other languages

English (en)

French (fr)

Other versions

CA2875205A1 (en

Inventor

Hiroshi Mori

Takami Tomiyama

Yoichi Matsumoto

Hiroshi Eguchi

Yuichi Kunori

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Teijin Ltd

Osaka Metropolitan University

Original Assignee

Teijin Pharma Ltd

Osaka City University PUC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-31

Filing date

2013-05-30

Publication date

2021-07-20

2013-05-30 Application filed by Teijin Pharma Ltd, Osaka City University PUC filed Critical Teijin Pharma Ltd

2013-12-05 Publication of CA2875205A1 publication Critical patent/CA2875205A1/en

2021-07-20 Application granted granted Critical

2021-07-20 Publication of CA2875205C publication Critical patent/CA2875205C/en

Status Active legal-status Critical Current

2033-05-30 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2875205A 2012-05-31 2013-05-30 Therapeutic agent or prophylactic agent for dementia Active CA2875205C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2012-124336		2012-05-31
JP2012124336		2012-05-31
PCT/JP2013/065090 WO2013180238A1 (ja)	2012-05-31	2013-05-30	認知症治療剤又は予防剤

Publications (2)

Publication Number	Publication Date
CA2875205A1 CA2875205A1 (en)	2013-12-05
CA2875205C true CA2875205C (en)	2021-07-20

Family

ID=49673425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2875205A Active CA2875205C (en)	2012-05-31	2013-05-30	Therapeutic agent or prophylactic agent for dementia

Country Status (30)

Country	Link
US (3)	US20150183854A1 (de)
EP (2)	EP2857039B1 (de)
JP (3)	JP5971659B2 (de)
KR (2)	KR102208283B1 (de)
CN (1)	CN104602708B (de)
AR (1)	AR091218A1 (de)
AU (2)	AU2013268364B2 (de)
BR (1)	BR112014029566A2 (de)
CA (1)	CA2875205C (de)
CY (1)	CY1122530T1 (de)
DK (1)	DK2857039T3 (de)
ES (2)	ES2763361T3 (de)
HR (1)	HRP20192267T1 (de)
HU (1)	HUE046919T2 (de)
IL (1)	IL235899B (de)
LT (1)	LT2857039T (de)
ME (1)	ME03587B (de)
MX (1)	MX361128B (de)
MY (1)	MY172458A (de)
NZ (1)	NZ630536A (de)
PH (1)	PH12014502669B1 (de)
PL (1)	PL2857039T3 (de)
PT (1)	PT2857039T (de)
RS (1)	RS59802B1 (de)
RU (1)	RU2657438C2 (de)
SG (2)	SG10201805410XA (de)
SI (1)	SI2857039T1 (de)
TW (2)	TWI700296B (de)
WO (1)	WO2013180238A1 (de)
ZA (1)	ZA201409186B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012106363A2 (en)	2011-01-31	2012-08-09	Intellect Neurosciences Inc.	Treatment of tauopathies
WO2012162179A1 (en) *	2011-05-20	2012-11-29	Oligomerix, Inc.	Tau protease compositions and methods of use
TWI700296B (zh) *	2012-05-31	2020-08-01	公立大學法人大阪市立大學	失智症治療劑或預防劑
EP2870176A4 (de)	2012-07-03	2016-09-28	Univ Washington	Anti-tau-antikörper
TWI734975B (zh)	2014-06-27	2021-08-01	美商Ｃ２Ｎ醫療診斷有限責任公司	人類化抗-tau抗體
WO2017189963A1 (en) *	2016-04-29	2017-11-02	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
JP6785372B2 (ja) *	2016-09-30	2020-11-18	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
CA3053379A1 (en)	2017-02-17	2018-08-23	Denali Therapeutics Inc.	Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) *	2017-02-27	2018-09-13	帝人ファーマ株式会社	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
CA3056573A1 (en)	2017-05-30	2018-12-06	Teijin Pharma Limited	Anti-igf-i receptor antibody
GEAP202215303A (en)	2017-10-02	2022-04-11	Merck Sharp & Dohme	Chromane monobactam compounds for the treatment of bacterial infections
JP6851549B2 (ja)	2017-10-16	2021-03-31	エーザイ・アール・アンド・ディー・マネジメント株式会社	抗タウ抗体及びその使用
JP7504026B2 (ja)	2018-04-06	2024-06-21	帝人ファーマ株式会社	Ｓｐｎｓ２中和抗体
EP3819378A4 (de)	2018-07-04	2022-09-14	Aichi Medical University	Oligonukleotide zur kontrolle von tau-splicing und deren verwendungen
CN110028583B (zh) *	2019-05-07	2020-09-11	温州医科大学	抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
GB2585252A (en)	2019-07-05	2021-01-06	Gen2 Neuroscience Ltd	Tau epitope and binding molecules
JP7429404B2 (ja) *	2019-08-06	2024-02-08	慶應義塾	タウ関連疾患モデルの製造方法
JP7718270B2 (ja)	2019-09-30	2025-08-05	ニプロ株式会社	血液試料を検体とするタウタンパク質検出方法
JP2023518281A (ja) *	2020-03-19	2023-04-28	ヴァスキュラーバイオサイエンスィズ	コロナウイルス生存率改善のためのｃａｒペプチド
CN116723856A (zh) *	2020-06-25	2023-09-08	默沙东有限责任公司	靶向丝氨酸413处磷酸化的tau的高亲和力抗体
CA3203800A1 (en) *	2021-02-19	2022-08-25	Eisai R&D Management Co., Ltd.	Anti-pt217 tau antibody
WO2023092004A1 (en)	2021-11-17	2023-05-25	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
JP2025535203A (ja)	2022-09-15	2025-10-23	ボイジャーセラピューティクスインコーポレイテッド	タウ結合化合物
WO2025122634A1 (en)	2023-12-05	2025-06-12	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
WO2026102093A1 (en)	2024-11-07	2026-05-15	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS587390B2 (ja)	1975-03-11	1983-02-09	ツキシマキカイカブシキガイシヤ	ア−クヨウセツホウホウ
JP3587390B2 (ja)	1994-03-17	2004-11-10	タカラバイオ株式会社	リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
WO1997034145A1 (fr) *	1996-03-13	1997-09-18	Mitsubishi Chemical Corporation	Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
US20080199471A1 (en) *	2002-03-01	2008-08-21	Bernett Matthew J	Optimized cd40 antibodies and methods of using the same
US8012936B2 (en)	2006-03-29	2011-09-06	New York University	Tau fragments for immunotherapy
US20070280935A1 (en) *	2006-04-07	2007-12-06	Bernd Bohrmann	Antibody that recognizes phosphorylated peptides
JP2009539406A (ja) *	2006-06-16	2009-11-19	エンビボファーマシューティカルズインコーポレイテッド	タウおよびアミロイド前駆体断片を発現する遺伝子組換えハエ
UA107571C2 (xx) *	2009-04-03	2015-01-26		Фармацевтична композиція
US8609097B2 (en)	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP4218794A3 (de)	2009-06-10	2023-09-13	New York University	Immunologisches targeting pathologischer tau-proteine
WO2012106363A2 (en) *	2011-01-31	2012-08-09	Intellect Neurosciences Inc.	Treatment of tauopathies
TR201102696U (tr) *	2011-05-27	2011-06-21	Turhal Sal�H	Bağlantısız hareketli ürün reklam standı.
TWI700296B (zh) *	2012-05-31	2020-08-01	公立大學法人大阪市立大學	失智症治療劑或預防劑
JP2018139530A (ja) *	2017-02-27	2018-09-13	帝人ファーマ株式会社	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

2013
- 2013-05-30 TW TW102119176A patent/TWI700296B/zh active
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/da active
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/ru active
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/de active Active
- 2013-05-30 PL PL13797290T patent/PL2857039T3/pl unknown
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/zh active Active
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/ko active Active
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/de unknown
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/de active Active
- 2013-05-30 HR HRP20192267TT patent/HRP20192267T1/hr unknown
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/lt unknown
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 TW TW109121902A patent/TWI777183B/zh active
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/ja not_active Ceased
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/ko active Active
- 2013-05-30 PT PT137972907T patent/PT2857039T/pt unknown
- 2013-05-30 AR ARP130101907 patent/AR091218A1/es active IP Right Grant
- 2013-05-30 RS RS20191640A patent/RS59802B1/sr unknown
- 2013-05-30 ES ES13797290T patent/ES2763361T3/es active Active
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/hu unknown
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/ja active Active
- 2013-05-30 ES ES19207405T patent/ES2973070T3/es active Active
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
- 2013-05-30 MX MX2014014187A patent/MX361128B/es active IP Right Grant
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/pt not_active Application Discontinuation
- 2013-05-30 SI SI201331636T patent/SI2857039T1/sl unknown
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/ja active Active
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/ja active Active
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/el unknown
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending

Also Published As

Publication number	Publication date
NZ630536A (en)	2017-03-31
EP3662931B1 (de)	2023-12-06
AU2018200413A1 (en)	2018-02-08
IL235899A0 (en)	2015-01-29
TW201410705A (zh)	2014-03-16
JP6406678B2 (ja)	2018-10-17
HK1210031A1 (en)	2016-04-15
PL2857039T3 (pl)	2020-05-18
PH12014502669B1 (en)	2020-02-19
SG10201805410XA (en)	2018-08-30
JP2016147902A (ja)	2016-08-18
MX361128B (es)	2018-11-28
ZA201409186B (en)	2015-12-23
KR20150027098A (ko)	2015-03-11
HUE046919T2 (hu)	2020-04-28
KR102208283B1 (ko)	2021-01-26
EP2857039B1 (de)	2019-11-20
AR091218A1 (es)	2015-01-21
EP3662931A1 (de)	2020-06-10
TW202041532A (zh)	2020-11-16
DK2857039T3 (da)	2019-12-16
US20200148753A1 (en)	2020-05-14
TWI700296B (zh)	2020-08-01
JPWO2013180238A1 (ja)	2016-01-21
AU2018200413B2 (en)	2019-10-17
MY172458A (en)	2019-11-26
ES2763361T3 (es)	2020-05-28
HRP20192267T1 (hr)	2020-03-20
MX2014014187A (es)	2015-06-04
RS59802B1 (sr)	2020-02-28
WO2013180238A1 (ja)	2013-12-05
TWI777183B (zh)	2022-09-11
US20220340646A1 (en)	2022-10-27
PT2857039T (pt)	2020-01-07
LT2857039T (lt)	2020-03-10
SI2857039T1 (sl)	2020-03-31
KR102133610B1 (ko)	2020-07-14
RU2657438C2 (ru)	2018-06-13
AU2013268364A1 (en)	2014-12-18
CN104602708B (zh)	2021-11-30
JP6620829B2 (ja)	2019-12-18
CA2875205A1 (en)	2013-12-05
US20150183854A1 (en)	2015-07-02
ES2973070T3 (es)	2024-06-18
BR112014029566A2 (pt)	2017-07-25
CN104602708A (zh)	2015-05-06
RU2014153099A (ru)	2016-07-20
IL235899B (en)	2019-03-31
JP5971659B2 (ja)	2016-08-17
EP2857039A1 (de)	2015-04-08
SG11201407878VA (en)	2015-01-29
EP2857039A4 (de)	2015-08-26
AU2013268364B2 (en)	2018-02-08
CY1122530T1 (el)	2021-01-27
JP2018111716A (ja)	2018-07-19
ME03587B (de)	2020-07-20
KR20200029619A (ko)	2020-03-18
PH12014502669A1 (en)	2015-02-02

Legal Events

Date	Code	Title	Description
2018-05-30	EEER	Examination request	Effective date: 20180523
2025-03-27	MPN	Maintenance fee for patent paid	Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12
2025-03-27	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250327
2025-03-27	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250327 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250327
2026-03-31	MPN	Maintenance fee for patent paid	Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13
2026-03-31	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260331
2026-03-31	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260331

Publication	Publication Date	Title
US20220340646A1 (en)	2022-10-27	Therapeutic agent or prophylactic agent for dementia
JP7012004B2 (ja)	2022-02-10	シヌクレイノパチーの治療のための薬剤、使用および方法
RU2760334C2 (ru)	2021-11-24	Моноклональные антитела к альфа-синуклеину для предотвращения агрегации тау-белка
JP2018139530A (ja)	2018-09-13	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TW201702273A (zh)	2017-01-16	用於治療的藥劑、用途及方法
EP4488292A9 (de)	2025-06-18	Therapeutikum für neurodegenerative erkrankungen
HK40031828A (en)	2021-03-19	Therapeutic agent or prophylactic agent for dementia
HK40031828B (en)	2024-05-17	Therapeutic agent or prophylactic agent for dementia
HK1210031B (en)	2022-04-22	Therapeutic agent or prophylactic agent for dementia
KR20260047599A (ko)	2026-04-08	신경 변성 질환의 치료제